Cargando…

Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication

Lysine-specific demethylase 1A (LSD1, KDM1A) specifically demethylates di- and monomethylated histones H3K4 and K9, resulting in context-dependent transcriptional repression or activation. We previously identified an irreversible LSD1 inhibitor T-3775440, which exerts antileukemic activities in a su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishikawa, Y, Nakayama, K, Morimoto, M, Mizutani, A, Nakayama, A, Toyoshima, K, Hayashi, A, Takagi, S, Dairiki, R, Miyashita, H, Matsumoto, S, Gamo, K, Nomura, T, Nakamura, K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623902/ https://www.ncbi.nlm.nih.gov/pubmed/28892104 http://dx.doi.org/10.1038/oncsis.2017.76

Ejemplares similares

Correction: Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication
por: Ishikawa, Y., et al.
Publicado: (2019)

The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma
por: Foster, Jennifer H., et al.
Publicado: (2021)

Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells
por: Wang, Xiaofang, et al.
Publicado: (2016)

Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis
por: Paiva, Cody, et al.
Publicado: (2017)

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes
por: Swords, R T, et al.
Publicado: (2017)

Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
por: Torka, Pallawi, et al.
Publicado: (2023)

A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
por: Bhatia, Shailender, et al.
Publicado: (2016)

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
por: Zhou, Xiaofei, et al.
Publicado: (2022)

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
por: Lockhart, A Craig, et al.
Publicado: (2018)

Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma
por: Torka, Pallawi, et al.
Publicado: (2020)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
por: Snow, Anson, et al.
Publicado: (2022)

The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis
por: Wolenski, F S, et al.
Publicado: (2015)

The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity
por: Malhab, Lara J. Bou, et al.
Publicado: (2016)

Phase I study assessing the mass balance, pharmacokinetics, and excretion of [(14)C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
por: Zhou, Xiaofei, et al.
Publicado: (2020)

The Nedd8‐activating enzyme inhibitor MLN4924 (TAK‐924/Pevonedistat) induces apoptosis via c‐Myc‐Noxa axis in head and neck squamous cell carcinoma
por: Zhang, Wenjuan, et al.
Publicado: (2018)

Inhibitors of CLK Protein Kinases Suppress Cell Growth and Induce Apoptosis by Modulating Pre-mRNA Splicing
por: Araki, Shinsuke, et al.
Publicado: (2015)

DNA Rereplication Is Susceptible to Nucleotide-Level Mutagenesis
por: Bui, Duyen T., et al.
Publicado: (2019)

Isolation and analysis of rereplicated DNA by Rerep-Seq
por: Menzel, Johannes, et al.
Publicado: (2020)

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours
por: Faessel, Hélène, et al.
Publicado: (2019)

Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates
por: Saliba, Antoine N., et al.
Publicado: (2022)

Prevention of DNA Rereplication Through a Meiotic Recombination Checkpoint Response
por: Najor, Nicole A., et al.
Publicado: (2016)

Loss of Geminin induces rereplication in the presence of functional p53
por: Melixetian, Marina, et al.
Publicado: (2004)

Replication fork instability and the consequences of fork collisions from rereplication
por: Alexander, Jessica L., et al.
Publicado: (2016)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Discovery of Nedd4 auto-ubiquitination inhibitors
por: Yong, Darren, et al.
Publicado: (2023)

Antiviral Properties of the LSD1 Inhibitor SP-2509
por: Harancher, Mitchell R., et al.
Publicado: (2020)

ABCG2 Overexpression Contributes to Pevonedistat Resistance
por: Kathawala, Rishil J., et al.
Publicado: (2020)

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
por: Fiskus, Warren, et al.
Publicado: (2014)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
por: Short, Nicholas J., et al.
Publicado: (2023)

Antitumor activity of LSD1 inhibitors in lung cancer
por: Mohammad, Helai P., et al.
Publicado: (2016)

Natural products as LSD1 inhibitors for cancer therapy
por: Fang, Yuan, et al.
Publicado: (2021)

Deregulated origin licensing leads to chromosomal breaks by rereplication of a gapped DNA template
por: Neelsen, Kai J., et al.
Publicado: (2013)

MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma
por: Tong, Shuai, et al.
Publicado: (2017)

A Metal-Based Inhibitor of NEDD8-Activating Enzyme
por: Zhong, Hai-Jing, et al.
Publicado: (2012)

Structure–Activity Relationship and In Silico Evaluation of cis- and trans-PCPA-Derived Inhibitors of LSD1 and LSD2
por: Niwa, Hideaki, et al.
Publicado: (2022)

A Selective Phenelzine Analogue Inhibitor of Histone Demethylase LSD1
por: Prusevich, Polina, et al.
Publicado: (2014)

The ATR-mediated S phase checkpoint prevents rereplication in mammalian cells when licensing control is disrupted
por: Liu, Enbo, et al.
Publicado: (2007)

Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway
por: Xu, Junfeng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lck8otegsqnqlcc7okvi0dbjo8